C5AR1 and COVID-19: Among the range of complement system inhibitors mentioned above, tesidolumab, a C5-blocking monoclonal antibody that prevents the formation of C5a and the membrane attack complex, was found to be effective in reducing the exaggerated inflammatory reaction and promoting clinical improvement in patients suffering from COVID-19 with severe disease [132].